JP2023539154A5 - - Google Patents

Info

Publication number
JP2023539154A5
JP2023539154A5 JP2023512354A JP2023512354A JP2023539154A5 JP 2023539154 A5 JP2023539154 A5 JP 2023539154A5 JP 2023512354 A JP2023512354 A JP 2023512354A JP 2023512354 A JP2023512354 A JP 2023512354A JP 2023539154 A5 JP2023539154 A5 JP 2023539154A5
Authority
JP
Japan
Prior art keywords
patient
administering
effective amount
intravenous solution
solution according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539154A (ja
Filing date
Publication date
Priority claimed from GBGB2012954.0A external-priority patent/GB202012954D0/en
Priority claimed from GBGB2012956.5A external-priority patent/GB202012956D0/en
Application filed filed Critical
Priority claimed from PCT/EP2021/073034 external-priority patent/WO2022038226A1/en
Publication of JP2023539154A publication Critical patent/JP2023539154A/ja
Publication of JP2023539154A5 publication Critical patent/JP2023539154A5/ja
Pending legal-status Critical Current

Links

JP2023512354A 2020-08-19 2021-08-19 エトポシドトニリベート製剤 Pending JP2023539154A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2012954.0A GB202012954D0 (en) 2020-08-19 2020-08-19 Etoposide toniribate formulation
GBGB2012956.5A GB202012956D0 (en) 2020-08-19 2020-08-19 Etoposide toniribate formulation
GB2012954.0 2020-08-19
GB2012956.5 2020-08-19
PCT/EP2021/073034 WO2022038226A1 (en) 2020-08-19 2021-08-19 Etoposide toniribate formulation

Publications (2)

Publication Number Publication Date
JP2023539154A JP2023539154A (ja) 2023-09-13
JP2023539154A5 true JP2023539154A5 (cg-RX-API-DMAC7.html) 2024-08-27

Family

ID=80322580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512354A Pending JP2023539154A (ja) 2020-08-19 2021-08-19 エトポシドトニリベート製剤

Country Status (7)

Country Link
US (1) US20230398069A1 (cg-RX-API-DMAC7.html)
EP (1) EP4199933A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023539154A (cg-RX-API-DMAC7.html)
KR (1) KR20230131815A (cg-RX-API-DMAC7.html)
AU (1) AU2021327164A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189720A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022038226A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4233837A1 (en) * 2022-02-24 2023-08-30 CellAct Pharma GmbH Solid and oral etoposide toniribate compositions
CN116983259A (zh) * 2023-09-27 2023-11-03 成都瑞尔医药科技有限公司 一种依托泊苷注射液的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69431071T2 (de) * 1993-12-29 2003-03-20 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
ES2354065T3 (es) * 2001-12-03 2011-03-09 Universitätsklinikum Charité Der Humboldt- Universität Zu Berlin Podofilotoxinas en calidad de agentes antiproliferativos.
JP4020256B2 (ja) * 2003-05-23 2007-12-12 日本化薬株式会社 前立腺癌の局所治療剤
EP2308467A3 (en) * 2005-06-17 2011-06-22 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
US9889147B2 (en) * 2010-04-16 2018-02-13 Cellact Pharma Gmbh Analogues of etoposide for the treatment of tumours
LT3228319T (lt) * 2011-04-28 2020-09-25 Oncopeptides Ab Liofilizuotas citotoksinių dipeptidų preparatas
SI3228319T1 (sl) * 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
GB2513299A (en) * 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells

Similar Documents

Publication Publication Date Title
JP2023541432A5 (cg-RX-API-DMAC7.html)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2013155188A5 (cg-RX-API-DMAC7.html)
JP2016034978A5 (cg-RX-API-DMAC7.html)
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
JP2020530857A5 (cg-RX-API-DMAC7.html)
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
JP2013541583A5 (cg-RX-API-DMAC7.html)
JP2016510326A5 (cg-RX-API-DMAC7.html)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
JP2020523356A5 (cg-RX-API-DMAC7.html)
CN111989095A (zh) 预防或治疗肿瘤疗法副作用的方法
JP2016519107A5 (cg-RX-API-DMAC7.html)
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
JP2018522028A5 (cg-RX-API-DMAC7.html)
MX2017011169A (es) Uso de citrato ferrico en el tratamiento de anemia por deficiencia de hierro.
JP2022532038A5 (cg-RX-API-DMAC7.html)
JP2019529569A5 (cg-RX-API-DMAC7.html)
WO2017013490A3 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
JP2018516920A5 (cg-RX-API-DMAC7.html)
KR20220083020A (ko) 알츠하이머병을 동반한 혈관성 치매를 치료하는 약제학적 복합제제
JP2010519274A5 (cg-RX-API-DMAC7.html)
RU2020123217A (ru) Противо-SARS-CoV-2 вирусное средство Антипровир